PositiveID to Use PCR Technology as Part of Shared Defense Contract with Leidos | GenomeWeb

NEW YORK (GenomeWeb) – Leidos and partner PositiveID have been awarded a contract from the US Defense Threat Reduction Agency (DTRA) to develop detection technologies for potential weapons of mass destruction.

Leidos is one of seven contractors eligible to compete for task orders under the DTRA contract, PositiveID said today. The multiple-award indefinite delivery/indefinite quantity contract has a five-year base period of performance, and if all options are exercised, it is valued at $4 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.